PUBLICATION
Effects of anti-osteoporosis drugs against dexamethasone-induced osteoporosis-like phenotype using a zebrafish scale-regeneration model
- Authors
- Saito, Y., Nakamura, S., Chinen, N., Shimazawa, M., Hara, H.
- ID
- ZDB-PUB-200403-201
- Date
- 2020
- Source
- Journal of Pharmacological Sciences 143(2): 117-121 (Journal)
- Registered Authors
- Keywords
- Glucocorticoid-induced osteoporosis (GIOP), Scale regeneration, Zebrafish
- MeSH Terms
-
- Animal Scales/pathology*
- Animal Scales/physiology*
- Animals
- Bone Density Conservation Agents/pharmacology
- Bone Density Conservation Agents/therapeutic use*
- Dexamethasone/adverse effects*
- Disease Models, Animal*
- Osteoporosis/chemically induced*
- Osteoporosis/drug therapy*
- Phenotype
- Regeneration*/drug effects
- Zebrafish
- PubMed
- 32220570 Full text @ J. Pharmacol. Sci.
Citation
Saito, Y., Nakamura, S., Chinen, N., Shimazawa, M., Hara, H. (2020) Effects of anti-osteoporosis drugs against dexamethasone-induced osteoporosis-like phenotype using a zebrafish scale-regeneration model. Journal of Pharmacological Sciences. 143(2):117-121.
Abstract
There are several animal models of glucocorticoid-induced osteoporosis (GIOP), but each requires a long time to evaluate drug effects. Zebrafish scales are classified as dermal bone and potentially represent a convenient animal model of GIOP because they rapidly regenerate following their removal. We clarified that dexamethasone-treated regenerating scales showed malformations, decreased size and circularity. Anti-osteoporosis drugs rescued the scale malformation phenotype eight-days following the removal of scales. Hence, the dexamethasone-induced regenerating scale malformation model may be a useful animal model for discovering drugs to treat GIOP.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping